Search results
Results from the WOW.Com Content Network
AV-COVID-19 AIVITA Biomedical, Inc., Ministry of Health (Indonesia) United States, Indonesia Dendritic cell vaccine (autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF) Phase I–II (202) [187] [188] Adaptive. Dec 2020 – Feb 2022, Indonesia (phase I), United States (phase I/II ...
In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus. [4] [24] In April 2021, the US Department of Defense discontinued funding of future phase III trials of INO-4800. [25]
The UCLA Broad Stem Cell Research Center supports several shared resources, [8] including research cores and infrastructure. It also offers training for UCLA undergraduate and graduate students, postdoctoral scholars and clinical fellows as well as undergraduates from California State University, Northridge through a special partnership. This ...
Former Senator Frist also supports stem cell research, despite having initially supported past restrictions on embryonic stem cell research. 2008 V.P. candidate Palin opposed embryonic stem cell research, which she said causes the destruction of life, thus this research is inconsistent with her pro-life position and she does not support it. [25]
There is other stem cell research that does not involve the destruction of a human embryo, and such research involves adult stem cells, amniotic stem cells, and induced pluripotent stem cells. In January 2009, the US Food and Drug Administration gave clearance to Geron Corporation for the first clinical trial of an embryonic stem-cell-based ...
Other stem-cell based therapies for type 1 and type 2 diabetes are also currently in development and in trials.. Stem-cell therapy reverses type 1 diabetes in case study. For this case study ...
During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1. [8] The candidate is a live replicating virus vaccine using a vaccinia virus vector. [9] Results from pre-clinical studies were published in Molecular Therapy in October 2021. [10]
The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate. [ 6 ] Clinical trials